Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

Merck's German-listed shares closed down 3.7%. Stamford, Connecticut-based SpringWorks, which listed its shares in New York in 2019, is a commercial-stage biotech firm that develops drugs to treat ...

Germany’s Merck MRK1.45%increase; green up pointing triangle KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics SWTX 7.53%increase; green up pointing ...

NEW YORK/FRANKFURT (Reuters) - Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks ...

Germany's Merck KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.

On Monday, Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks Therapeutics Inc (NASDAQ:SWTX), which has a market ...